Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers.

Share this postShare on Google+Share on LinkedInShare on FacebookTweet about this on TwitterEmail this to someone

The Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers. Drs. Corbin Bachmeier, Daniel Paris, and Michael Mullan at the Roskamp Institute have been working on ways to improve the removal of the Alzheimer amyloid peptide from the brain. Using antibodies to amyloid and in an vitro model of the blood brain barrier, the Roskamp Institute researchers have shown that certain antibodies can enhance the clearance of amyloid from the brain side to the blood side. However, they also showed that other antibodies were not able to do this. The researchers explained that the difference in ability to remove amyloid has to do with a receptor called RAGE. The RAGE receptor is responsible for taking amyloid from the blood into the brain. The researchers suggested that the antibodies which bind amyloid but block its uptake by RAGE keep amyloid in the blood and thus, allow its removal from the body by the liver. As a consequence of removal of amyloid from the blood, more amyloid flows from the brain into the blood. However, antibodies which bind amyloid but still allow it to be taken up by the RAGE receptor do not stop it from being taken back from the blood into the brain. Thus, antibodies which bind amyloid and block its uptake by the RAGE receptor are thought to be most preferable. Antibodies to the Alzhemier amyloid peptide are being developed by a number of pharmaceutical companies to encourage the removal of amyloid from the Alzheimer brain.

The Roskamp Institute, under the leadership of Drs. Michael Mullan and Fiona Crawford, is dedicated to finding new treatments and cures for Alzheimer’s disease and related disorders.

Microcirculation. 2011 Jul;18(5):373-9. Epitope-dependent effects of Beta-amyloid antibodies on Beta-amyloid clearance in an in vitro model of the blood-brain barrier. Bachmeier CJ, Beaulieu-Abdelahad D, Mullan M, Paris D.

 

For more information visit http://www.michaelmullan.biz

michael mullan, alzheimer, mullan alzheimer, mullan roskamp, roskamp institute, amyloid